West Pharmaceutical Services Inc (WST)
OvervaluedFundamental
66
मूल्य
$366.07
मार्केट कैप
$26.44B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$3.33B
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$565M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$469M
कुल इक्विटी
$3.18B
कुल देनदारियाँ
$1.09B
Current Ratio
2.82
Interest Coverage
151.20
Debt/EBITDA
0.42
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$258.38
वर्तमान मूल्य
$366.07
Margin of Safety
-41.7%
Fair Value सीमा
$167.95 - $348.82
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
47.47
ROE
15.5%
P/B Ratio
8.73
P/FCF
59.72
Gross Margin
36.8%
ROIC
15.6%
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
15.6%
WACC
10.7%
ROIC − WACC
+4.9 pp
ROIC पूंजी की लागत से अधिक है — कंपनी शेयरधारकों के लिए मूल्य सृजित कर रही है।
Fundamental विश्लेषण मानदंड
पास (21)
- EPS shows upward trend
- EPS CAGR 6.05%
- Price CAGR 15.10%
- ROIC 15.6%
- Gross Margin 36.8%
- Debt/Equity ratio
- Operating Margin 20.5%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 18.5%
- Revenue Growth 5Y 7.4%
- Analyst Consensus 91% Buy
- Earnings Surprise avg 16.0%
- Earnings Quality (OCF/NI) 1.17
- Share Dilution -1.3%
- Net Margin Trend 17.0% vs 16.5%
- Piotroski F-Score 7/9
फेल (6)
- P/FCF 59.72
- P/B Ratio 8.73
- CapEx intensity
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 5.59
अनुपलब्ध (1)
- Dividend Payout NaN%
Piotroski F-Score
मजबूत वित्तीय स्वास्थ्य
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
संस्थागत होल्डिंग
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Robert W. McMahon C.M.A. | Senior VP & CFO | 56 |
| Ms. Annette F. Favorite | Chief HR Officer & Senior VP | 60 |
| Mr. Shane A. Campbell | SVP & Chief Proprietary Segment Officer | 45 |
| Mr. Michel Lagarde | President, CEO & Director | 50 |
| Mr. Chad R. Winters | VP of Finance & Chief Accounting Officer | 46 |
| Dr. Devesh Mathur | Senior VP & CTO | - |
| Mr. John P. Sweeney C.F.A. | Vice President of Investor Relations | - |
| Mr. Norman D. Finch Jr. | Senior VP, General Counsel & Corporate Secretary | 60 |
| Ms. Michele Polinsky | Vice President of Global Communications | - |
| Mr. Rudy J. Poussot | Senior Vice President of Strategy & Corporate Development | 55 |
Audit जोखिम
10
बोर्ड जोखिम
9
मुआवजा जोखिम
5
शेयरधारक अधिकार जोखिम
4
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
दस्तावेज़
- दस्तावेज़ देखें
वार्षिक रिपोर्ट (10-K)
कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।
दाखिल तिथि: 2026-02-17
- दस्तावेज़ देखें
तिमाही रिपोर्ट (10-Q)
पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।
दाखिल तिथि: 2026-07-23
- दस्तावेज़ देखें
विशेष रिपोर्ट (8-K)
किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।
दाखिल तिथि: 2026-07-23
via SEC EDGAR
आय का इतिहास
via SEC EDGAR
Latest News
Recent headlines for WST, sourced from Markets Gazette.
- 4/23/2026POSITIVEWest Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1
West Pharmaceutical Services Inc. reported Q1 results that surpassed analyst expectations, driven by robust demand for GLP-1 drug delivery components. The company has consequently raised its full-year 2026 financial guidance, signaling strong confidence in continued growth. Furthermore, West Pharmaceutical announced a new $1 billion share repurchase program, indicating a commitment to returning capital to shareholders. This combination of exceeding current performance, improving future outlook, and enhancing shareholder value makes the stock an attractive prospect for investors.
via Markets Gazette